Transmissible spongiform encephalopathy

Transmissible spongiform encephalopathies (TSEs), also known as prion diseases,<ref name="ninds">Template:Cite web</ref> are a group of progressive, incurable, and invariably fatal conditions that are associated with the degeneration of the nervous system in many animals, including humans, cattle, and sheep. Strong evidence supports the once unorthodox hypothesis that prion diseases are transmitted by abnormally shaped protein molecules known as prions.<ref name="Prusiner Prions">Template:Cite journal</ref><ref name= "Wadsworth 2010">Template:Cite journal</ref> Prions consist of a protein called the prion protein (PrP).<ref name="Prusiner Prions"/> Misshapen PrP (often referred to as PrP^Sc) conveys its abnormal structure to naive PrP molecules by a crystallization-like seeding process. Because the abnormal proteins stick to each other, and because PrP is continuously produced by cells, PrP^Sc accumulates in the brain, harming neurons and eventually causing clinical disease.<ref name="Prusiner Prions"/><ref name="Aguzzi 2009">Template:Cite journal</ref><ref name= "Wadsworth 2010"/>

Prion diseases are marked by mental and physical deterioration that worsens over time.<ref>Template:Cite journal</ref><ref name="Wadsworth 2007">Template:Cite journal</ref> A defining pathologic characteristic of prion diseases is the appearance of small vacuoles in various parts of the central nervous system that create a sponge-like appearance when brain tissue obtained at autopsy is examined under a microscope.<ref name="Prusiner Prions"/><ref name= "Wadsworth 2010"/> Other changes in affected regions include the buildup of PrP^Sc, gliosis, and the loss of neurons.<ref name="Ritchie 2025">Template:Cite journal</ref>

In non-human mammals, the prion diseases include scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle (popularly known as "mad cow disease") chronic wasting disease (CWD) in deer and elk, and others.<ref name= "Imran 2011">Template:Cite journal</ref> Prion diseases of humans include Creutzfeldt–Jakob disease, Gerstmann–Sträussler–Scheinker syndrome, fatal familial insomnia, kuru, and variably protease-sensitive prionopathy.<ref name="Wadsworth 2007"/><ref name="Ironside 2017">Template:Cite book</ref> Creutzfeldt-Jakob disease has been divided into four subtypes: sporadic (idiopathic) (sCJD), hereditary/familial (fCJD), iatrogenic (iCJD) and variant (vCJD). These diseases form a spectrum of related conditions with overlapping signs and symptoms.

Prion diseases are unusual in that their aetiology may be genetic, infectious, or idiopathic.<ref name="Prusiner Prions"/> Genetic (inherited) prion diseases result from rare mutations in PRNP, the gene that codes for PrP (see Genetics, below). Unlike conventional infectious diseases, which are spread by agents with a DNA or RNA genome (such as viruses or bacteria), prion diseases are transmitted by prions, the active material of which is solely abnormal PrP. Infection can occur when the organism is exposed to prions through ingestion of infected foodstuffs or via iatrogenic means (such as treatment with biologic material that had been inadvertently contaminated with prions).<ref>Template:Cite journal</ref> The variant form of Creutzfeldt–Jakob disease in humans is caused by exposure to BSE prions.<ref>Template:Cite web</ref><ref>Template:Cite web</ref><ref>Template:Cite journal</ref> Whereas the naturally occurring transmission of prion diseases among nonhuman species is relatively common, prion transmission to humans is very rare; rather, the majority of human prion diseases are idiopathic in nature<ref name="Ritchie 2021">Template:Cite journal</ref> (see Infectivity, below). Sporadic prion diseases occur in the absence of a mutation in the gene for PrP or a source of infection.

Although research has shown that the infectious capacity of prions is encoded in the conformation of PrP^Sc,<ref name="Prusiner Prions"/><ref name="Aguzzi 2009"/> it is likely that auxiliary substances contribute to their formation and/or infectivity. Purified PrP^C appears to be unable to convert to the infectious PrP^Sc form in a protein misfolding cyclic amplification (PMCA) assay unless other components are added, such as a polyanion (usually RNA) and lipids. These other components, termed cofactors, may form part of the infectious prion, or they may serve as catalysts for the replication of a protein-only prion.<ref name="Lee KS 2007">Template:Cite journal</ref> Considering that the cofactors can be produced by chemical synthesis instead of being sourced solely from infected cases (or any animal at all), it is fair to say that they do not form the infectious part of the prion. However, these catalysts (especially the polyanion) do have a tendency to be included in the prion aggregate, which makes seeding new aggregates easier in vitro.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>

Classification

Prion diseases can be classified according to the characteristics of the prions that are involved in each type of disease. PrP^C refers to "Cellular" PrP, the normal form of the protein that is not misfolded.<ref name="sci5621">Template:Cite journal</ref> PrP^Sc refers to the scrapie-associated form of PrP,<ref name="sci5621"/> although it is often used as a general term for misfolded (disease-causing) PrP. Other generic terms for disease-associated PrP are PrP^Res ("Res" stands for "Resistant" to protease),<ref name="Priola 1994">Template:Cite journal</ref> and PrP^D ("D" for "Disease").<ref name="Lezmi 2004">Template:Cite journal</ref> In the Table below, different prion types are classified based on the disease to which they are linked. Differences in shape among the different prion protein forms are incompletely understood, although new methods such as cryo-electron microscopy are beginning to address this problem.<ref name="Manka 2019">Template:Cite journal</ref><ref name="Artikis 2022">Template:Cite journal</ref>

Known spongiform encephalopathies

ICTVdb Code	Disease name	Natural host	Prion name	PrP isoform	Ruminant
Non-human mammals
90.001.0.01.001.	Scrapie	Sheep and goats	Scrapie prion	PrPSc	Yes
90.001.0.01.002.	Transmissible mink encephalopathy (TME)	Mink	TME prion	PrPTME	No
90.001.0.01.003.	Chronic wasting disease (CWD)	Elk, white-tailed deer, mule deer and red deer	CWD prion	PrPCWD	Yes
90.001.0.01.004.	Bovine spongiform encephalopathy (BSE) commonly known as "mad cow disease"	Cattle	BSE prion	PrPBSE	Yes
90.001.0.01.005.	Feline spongiform encephalopathy (FSE)	Cats	FSE prion	PrPFSE	No
90.001.0.01.006.	Exotic ungulate encephalopathy (EUE)	Nyala and greater kudu	EUE prion	PrPEUE	Yes
	Camel spongiform encephalopathy (CSE)<ref>Template:Cite news</ref>	Camel		PrPCSE	Yes
Human diseases
90.001.0.01.007.	Kuru	Humans	Kuru prion	PrPKuru	No
90.001.0.01.008.	Creutzfeldt–Jakob disease (CJD)		CJD prion	PrPsCJD	No
	Variant Creutzfeldt–Jakob disease (vCJD, nvCJD)		vCJD prion<ref>Believed to be identical to the BSE prion.Template:By whom</ref>	PrPvCJD
90.001.0.01.009.	Gerstmann-Sträussler-Scheinker syndrome (GSS)		GSS prion	PrPGSS	No
90.001.0.01.010.	Fatal insomnia (FFI)		FFI prion	PrPFFI	No
	Familial spongiform encephalopathy<ref>Template:Cite journal</ref>

Pathology

The degenerative tissue damage caused by prion disease in the nervous system is characterised by four features: spongiform change (the presence of many small vacuoles); the death of neurons; astrocytosis (abnormal increase in the number of astrocytes); and deposits of abnormal PrP (some of which have the characteristics of amyloid).<ref name=DeArmond>Template:Cite book</ref> These neuropathological features have formed the basis of the histological diagnosis of prion diseases for many years, although it has been recognized that these changes are highly variable both from case to case and within the central nervous system in individual cases.<ref>Template:Cite journal</ref><ref name=DeArmond/> In humans, prion diseases with different genetic or infectious causes often have different patterns of pathology. For instance, amyloid plaques are rare in most prion diseases, but they are common in some diseases such as kuru and variant CJD. Owing to the rarity of amyloid per se in prion diseases, it is thought that non-amyloid forms of PrP^Sc are responsible for neurodegeneration.<ref name=DeArmond/> In rare instances of human prion disease, tauopathy resembling the neurofibrillary tangles in Alzheimer's disease is present, highlighting the many ways in which the pathology of prion diseases can vary.<ref name=DeArmond/> Despite this variation, all prion diseases have in common the buildup of abnormal PrP in the nervous system.

Micrograph of prion protein (PrP) deposition (brown) in the cerebral cortex of a person who had died with Creutzfeldt-Jakob disease (CJD). Immunohistochemical stain for PrP; Nissl counterstain (blue); scale bar = 100 microns (0.1mm).

Signs and symptoms

The clinical signs of prion diseases in humans vary, but the classical signs of sporadic CJD include rapidly progressive dementia, behavioral abnormalities, disturbances of movement such as lack of coordination and/or an unsteady gait (ataxia), and involuntary jerking movements (myoclonus).<ref name="Geschwind MD">Template:Cite journal</ref><ref name="Will RG 2017">Template:Cite journal</ref> Patients also may experience unusual sensations, insomnia, and confusion, and in the later stages of the disease they may lose the ability to move or speak.<ref name="Collinge Prion Diseases of Humans">Template:Cite journal</ref> The clinical course of prion diseases usually is relatively rapid (the mean survival time for sporadic CJD is 6 months, although it can sometimes be a year or more),<ref name="Geschwind MD"/> and all prion diseases are ultimately fatal. Studies of heritable and acquired (infectious) prion diseases have found that the relatively brief symptomatic phase is preceded by a long silent phase during which the pathology develops in the brain. For example, the incubation period for kuru following infection with prions can exceed 50 years.<ref name= "Wadsworth 2010"/> The highly variable nature of signs and symptoms in prion diseases makes them difficult to distinguish from other neurologic disorders based solely on their clinical traits.<ref name="Geschwind MD"/>

Genetics

Only 10-15% of human prion disease cases are heritable; most of them occur sporadically, that is, in the absence of known genetic mutations or infection.<ref name="Mead Prion disease genetics"/><ref name="Geschwind MD"/> However, discovery of the gene involved in heritable prion diseases was a critical event in linking abnormalities of the prion protein to genetic, infectious and idiopathic prion diseases.<ref name="Prusiner Prions"/> All familial forms of prion disease are caused by inherited mutations in the PRNP gene, which codes for PrP.<ref name="Mead Prion disease genetics">Template:Cite journal</ref> Three general types of PRNP mutation can lead to disease: point mutations that change an amino acid in a specific part of PrP; a premature stop codon that results in shortened PrP molecules; or the insertion of extra octapeptide repeats that abnormally lengthen part of the protein.<ref name="Mead Prion disease genetics"/> These mutations increase the likelihood that PrP will fold into the wrong shape (PrP^Sc) and amplify within the nervous system. Different mutations can cause prion diseases with different clinical and pathological characteristics.<ref name="Mead Prion disease genetics"/>

The normal function(s) of PrP are incompletely understood, although it is likely that the protein participates in many biochemical processes.<ref name="Cha S 2023">Template:Cite journal</ref> It is expressed throughout much of the body, and is especially abundant in the nervous system.<ref name="Wulf 2017">Template:Cite journal</ref> When the PRNP gene is inactivated in animals such as mice, cattle and goats, the PrP-deficient animals are resistant to prion infection.<ref name="Wulf 2017"/> Although the absence of a functional PRNP gene can result in changes in various tissues, the animals are viable and appear to be relatively normal, at least at young ages.<ref name="Wulf 2017"/>

Infectivity

Scrapie was suspected to be infectious among sheep in the earliest days from which reliable reports are available.<ref name="Schneider 2008">Template:Cite journal</ref> However, it wasn't until the 1930s that the inoculation experiments of Jean Cuillé and Paul-Louis Chelle convincingly demonstrated the infectivity of scrapie<ref name="Brown Bradley">Template:Cite journal</ref><ref name="Schneider 2008"/> (see History, below). In 1959, William Hadlow recognized striking similarities between scrapie and the kuru cases described in humans by D. Carleton Gajdusek.<ref name="Hadlow 2008">Template:Cite journal</ref> The shared features of these human and nonhuman diseases prompted Gajdusek to conduct a series of experiments in which he demonstrated that human spongiform encephalopathies are transmissible to nonhuman primates. His research group reported the transmissibility of kuru in 1966,<ref name="Gajdusek 1966">Template:Cite journal</ref> Creutzfeldt-Jakob disease (CJD) in 1968,<ref name="Gajdusek 1968">Template:Cite journal</ref> and Gerstmann–Sträussler–Scheinker syndrome (GSS) in 1981.<ref name="Masters 1981">Template:Cite journal</ref> These experiments showed that human spongiform encephalopathies, like those in nonhuman species, can be infectious; because the diseases have an unusually long incubation period following exposure to the infectious agent,<ref name="Will RG 2017"/> the agent was sometimes referred to as a 'slow virus'.<ref name="Zabel 2015">Template:Cite journal</ref><ref name="Prusiner Prions"/> The infectious agent was not shown with reasonable certainty to be primarily a protein until the work of Stanley Prusiner gave rise to the prion concept in 1982.<ref name="Prusiner 1982">Template:Cite journal</ref><ref name="Prusiner Prions"/>

Infectious prion diseases in humans are uncommon and decreasing in incidence. Iatrogenic versions have been recognized since the 1980's: Creutzfeldt–Jakob disease has been inadvertently transmitted to patients via injections of growth hormone harvested from human cadaveric pituitary glands, via cadaveric dural allografts, and (more rarely) via corneal transplants, transfusion of blood products, and exposure to contaminated instruments used for brain surgery.<ref name="Geschwind MD"/> Prions can survive heating in the autoclave, a method used for the conventional sterilization of surgical instruments.<ref name="Fernie 2012">Template:Cite journal</ref> For this reason, special precautions need to be taken to ensure the complete sterility of neurosurgical instruments.<ref name="Bonda 2016">Template:Cite journal</ref>

Dietary consumption of affected animal parts can transmit prion disease, especially in nonhuman species in which infectious prion diseases are relatively common. In these instances, how the agent gains wider access to the body is not entirely clear; besides the apparent transmission of prions via the alimentary tract, transmissible spongiform encephalopathies may be naturally acquired when prion-containing material comes in contact with damaged tissues such as the gums, skin, or conjunctiva.<ref name="Kovacs 2008">Template:Cite journal</ref> In humans, infection via consumption is very rare, two well-known examples being kuru and variant Creutzfeldt-Jakob disease (vCJD).<ref name="Wadsworth 2007"/> Kuru is a (now extinct) prion disease that reached epidemic proportions in the mid-20th century in the Fore people of Papua New Guinea. Until the practice was abandoned in the mid-20th century, the Fore people would consume their dead as a funerary ritual.<ref>Template:Cite journal</ref> With the cessation of ritual cannibalism, new cases of kuru slowly ceased to appear.<ref name="Geschwind MD"/> A more well-known infectious human prion disease is vCJD, a zoonotic prion disease that is caused by the consumption of tissues from cows with bovine spongiform encephalopathy (BSE).<ref name="Will RG 2017"/> Cows are thought to have acquired BSE by consuming food that contained meat products derived from animals with prion disease, possibly sheep with scrapie.<ref name="Geschwind MD"/> Fortunately, vCJD has largely been eliminated by efforts to exclude tainted meat products from the food chain. Regulations in many developed countries now ban the use of rendered ruminant proteins in ruminant feed as a precaution against the spread of prion infection in cattle and other animals.<ref name="Heim D">Template:Cite journal</ref>

Prions cannot be transmitted through the air, through touching, or by most other forms of casual contact. However, they may be transmitted through contact with infected tissue, bodily fluids, or contaminated medical instruments. Normal sterilization procedures such as boiling or irradiating materials fail to render prions non-infective. However, treatment with strong, almost undiluted bleach and/or sodium hydroxide, or heating to a minimum of 134 °C, does destroy prions.<ref>Template:Cite web</ref>

Epidemiological surveillance has identified cases of atypical bovine spongiform encephalopathy (BSE) and scrapie in livestock, as well as chronic wasting disease (CWD) in cervids, highlighting the zoonotic potential of prion diseases and their impact on animal and human health.<ref name="Belay Schonberger public health impact"/>

Other hypotheses

The infectious protein hypothesis has become the prevailing explanation for the causation of prion diseases.<ref name="Geschwind MD"/><ref name="Prusiner Prions"/><ref name="Zabel 2015"/> However, in the years following the recognition of their infectivity, other hypotheses regarding the infectious agent have been proposed. These include unorthodox forms of carbohydrates, lipids, nucleic acids, or unusual or cryptic infectious agents.<ref name="Prusiner Prions"/> With respect to causation by nucleic acid-based infectious agents, a hypothesis championed by Laura Manuelidis invokes a cryptic viral agent,<ref name="Manuelidis 2013">Template:Cite journal</ref> and another proposed by Frank O. Bastian holds that Spiroplasma infection, specifically Spiroplasma mirum, is a cause of transmissible spongiform encephalopathies.<ref>Template:Cite journal</ref> However, no alternative hypothesis has garnered sufficient support to displace the prion paradigm.<ref name="Prusiner Prions"/><ref name="Zou 2005">Template:Cite journal</ref><ref name="Soto 2010">Template:Cite journal</ref>

Diagnosis

The variable presentation of prion diseases and their rapid progression following the appearance of signs and symptoms present a special challenge for diagnosis.<ref name="Shimamura 2025">Template:Cite journal</ref> Because the early signs of disease can mimic those in other brain disorders, the diagnosis of prion disease is often delayed.<ref name="Geschwind MD"/> Upon clinical examination, sporadic CJD (the most frequent human prion disease) is suspected when the patient presents with rapidly progressing deterioration of cognition and movement. The diagnosis can be supported by the following tests: 1) Electroencephalogram (EEG) - in CJD, the pattern of brain waves changes over the course of the disease, one typical abnormality being periodic sharp and slow wave complexes in the electrical signal; 2) Cerebrospinal fluid (CSF) tests, in particular, measurement of the 14-3-3 protein, tau protein, and neurofilament light chain, all of which increase in prion diseases; 3) Magnetic resonance imaging (MRI) can detect characteristic changes in the structure of the brain; and 4) Real-time Quaking Induced Conversion (RT-QuIC) is used to detect the presence of abnormal PrP in the CSF.<ref name="Zerr 2022">Template:Cite journal</ref><ref name="Shimamura 2025"/><ref name="Hermann 2021">Template:Cite journal</ref> Although many of the changes detected by these tests occur in other diseases, combining the test results can establish the presence of prion disease with high Sensitivity and specificity. False positive diagnoses, though rare, are still possible; therefore, definitive diagnosis of prion diseases requires direct examination of brain tissue.<ref name="Shimamura 2025"/>

Treatment

There are currently no known ways to cure or prevent prion disease.<ref>Template:Cite web</ref> Certain medications slow down the progression of the disease in mice, but these have not been found to be effective in trials with human patients.<ref>Template:Cite web</ref> Ultimately, supportive care is the only option for easing the burden of disease in affected individuals.

Epidemiology

Prion diseases are unique in medicine in that they can be sporadic, genetic, or infectious in origin.<ref name="Geschwind MD"/><ref name="Prusiner Prions"/> There are a number of different prion diseases of humans and nonhuman species, each with its own characteristics (such as the primary host species, incidence, disease course, and pathology).<ref name=DeArmond/><ref name="Imran 2011 hu">Template:Cite journal</ref><ref name= "Imran 2011"/> In humans, the most common prion disease is CJD, which is estimated to occur worldwide in 1 to 2 persons per million per year.<ref name="Uttley 2020">Template:Cite journal</ref> Of these, approximately 85% are sporadic, 10-15% are genetic, and less than 1% are acquired by infection.<ref name="Geschwind MD"/><ref name="Uttley 2020"/> The incidence of sCJD increases with age, and it is most likely to appear between the ages of 55 and 75.<ref name="Geschwind MD"/> Although there may be subtle sex differences, males and females appear to be affected at a similar rate.<ref name="Holman 2010">Template:Cite journal</ref> Analyses in several countries suggest that the incidence of sCJD has risen in recent years.<ref name="Nishimura 2020">Template:Cite journal</ref><ref name="Uttley 2020"/><ref name="Crane 2024">Template:Cite journal</ref> This increase may be due in part to improved detection of the disease, although the growing elderly population is also a possible factor.<ref name="Nishimura 2020"/><ref name="Uttley 2020"/><ref name="Crane 2024"/> Much less common sporadic prion diseases include sporadic fatal insomnia (sFI) and variably protease sensitive prionopathy (VPSPr).<ref name="Appleby 2022">Template:Cite journal</ref>

Genetic (heritable) human prion diseases are caused by changes in the PRNP gene, which codes for PrP.<ref name="Appleby 2022"/> Three main categories of genetic prion disease are genetic Creutzfeldt-Jakob disease (gCJD), Gerstmann-Sträussler-Scheinker syndrome (GSS), and fatal familial insomnia (FFI).<ref name="Appleby 2022"/> Of these, the most frequently occurring type is gCJD, whereas FFI is extremely rare.<ref name="Geschwind MD"/> In addition to the mutations in PRNP that cause disease, there are variations in the PRNP gene that can increase or decrease the likelihood of developing all three aetiological subtypes of prion disease (genetic, infectious and sporadic).<ref name="Appleby 2022"/><ref name="Geschwind MD"/><ref name="Nafe 2023"/>

Infectious prion diseases in humans are very rare, historically accounting for less than 1% of cases; they include kuru, iatrogenic CJD (iCJD) and variant CJD (vCJD).<ref name="Ritchie 2021"/> Humans have been exposed to prions via contaminated foodstuffs, human cadaver-derived biologics (cadaveric hormones or cadaveric tissue grafts), or contaminated surgical instruments.<ref name="Appleby 2022"/> From 1957 until 2004, more than 2700 cases of kuru among the Fore people of Papua New Guinea were documented.<ref name="Collinge 2068–2074">Template:Cite journal</ref> With the cessation of endocannibalism beginning in the 1950s, the number of cases began to decline, and today the disease is considered to be eradicated.<ref name="Nafe 2023">Template:Cite journal</ref>

Of the approximately 500 cases of known iatrogenic CJD, most have been recipients of cadaveric pituitary hormones (200 cases, mostly in France) or cadaveric dura mater grafts (over 200 cases, mostly in Japan).<ref name="Nafe 2023"/> The rest of the iCJD cases have been very uncommon; these have involved corneal transplants (2-10 cases), intracranial exposure to contaminated EEG electrodes (2 cases), exposure to contaminated surgical instruments (4 cases), or transfusion of blood (3 cases).<ref name="Bonda 2016"/><ref name="Nafe 2023"/>

The variant form of CJD resulted from exposure of humans to prion-infected meat from cows with BSE.<ref name="Houston 2019">Template:Cite journal</ref><ref name="Nafe 2023"/> As of 2021, a total of 232 cases of vCJD had been reported worldwide.<ref name="Nafe 2023"/> Of these, most were in the United Kingdom (178 cases) and France (28 cases), with the remaining 26 cases appearing in various other countries.<ref name="Nafe 2023"/> All but one of these vCJD patients had a specific polymorphism (MM) at codon 129 of the PRNP gene, underscoring the importance of this gene locus as a modifier of susceptibility to prion disease.<ref name="Nafe 2023"/> Removal of cattle with prion disease from the food chain has brought the vCJD crisis to an end, although there is still some concern that people with certain polymorphisms of PRNP may yet develop disease after a longer incubation period.<ref name="Appleby 2022"/> In general, an improved understanding of prions and their transmissibility has greatly reduced the risk of infectious human prion diseases.<ref name="Brown P 2012">Template:Cite journal</ref><ref name="Norrby 2011">Template:Cite journal</ref>

In nonhuman species, the epidemiology of prion diseases differs from that in humans in that most cases are infectious in origin.<ref name= "Imran 2011"/><ref name="Houston 2019"/> Scrapie can be transmitted among sheep and goats in captivity, and chronic wasting disease (CWD) is unusual in that it is spreading both in captive and wild cervid populations, especially in North America.<ref name="Mori 2024">Template:Cite journal</ref> CWD was first identified in captive cervids in Colorado (USA) in 1967, and its distribution has since expanded to include many areas of North America as well as other countries.<ref name="Mori 2024"/> CWD is highly infectious, and it is transmissible via direct contact between animals or by contact with prion-contaminated materials.<ref name="Mori 2024"/> Infected animals can shed prions in saliva, feces and urine into the environment, and the prions can remain infectious for years thereafter.<ref name="Mori 2024"/>

Other nonhuman prion diseases mostly have resulted from feeding animals prion-contaminated food; in addition to BSE, these include transmissible mink encephalopathy, exotic ungulate spongiform encephalopathy and feline spongiform encephalopathy.<ref name= "Imran 2011"/> In the 1980s and 1990s, bovine spongiform encephalopathy (BSE, or "mad cow disease") spread in cattle at an epidemic rate, mostly in the UK.<ref name="Houston 2019"/> How the first cases of BSE arose is not known, but the epidemic was driven by feeding cattle meat and bone meal that contained the processed remains of infected animals.<ref name="Houston 2019"/> The bovine epidemic peaked in 1992 at 37,000 confirmed cases; as a result of a ban on feeding meat and bone meal to cattle, the numbers declined to single digits after 2011.<ref name="Houston 2019"/> Human consumption of meat from BSE-infected cattle caused an outbreak of variant CJD (see above). In the case of some newly emerging (or newly discovered) nonhuman prion diseases, such as CWD in Scandinavia and a prion disease of camels, the origins are sometimes unknown.<ref name="Houston 2019"/> While the transmission of prion disease from nonhumans to humans appears to be uncommon, the potential for zoonotic infection was highlighted by the BSE epidemic, and this possibility remains a concern among public health specialists.<ref name="Belay Schonberger public health impact">Template:Cite journal</ref><ref name="Houston 2019"/>

History

First reports of scrapie in sheep

The early history of transmissible spongiform encephalopathies is essentially the history of scrapie.<ref name="Schneider 2008"/> Reports of diseases resembling prion diseases can be found in the ancient literature,<ref name="McAlister Sacred disease of our times">Template:Cite journal</ref> but whether these disorders are actually transmissible spongiform encephalopathies is not known. The ascertainable history of transmissible spongiform encephalopathies begins in the mid-1700s with a German language description of scrapie in 1750<ref name="Schneider 2008"/> and an English report in the British House of Commons in 1755.<ref name="Brown Bradley"/> At the time, scrapie was better known among farmers and shepherds than veterinarians, in part because those who relied on the animals for their livelihood were encouraged to hide disease in their flocks from the authorities.<ref name="Schneider 2008"/> Based on the scanty literature of the time, scrapie was present in sheep herds at least as early as 1732.<ref name="Brown Bradley"/><ref name="Schneider 2008"/>

A report by J.G. Leopoldt in 1750 clearly remarks that scrapie is contagious: "Therefore, the very best a shepherd can do who has caught sight of an animal that has fallen ill with scrapie, is to cull the animal and slaughter it for the nobleman's servants. Thus, it is advisable for a shepherd to immediately separate such an animal from the healthy live-stock, as this disease is contagious and can cause great damage to the flock".<ref name="Schneider 2008"/> Nevertheless, many other causes of scrapie were suspected, including (among others) miasmata, atmospheric conditions, nutrition, age, inbreeding, and sexual characteristics of the rams.<ref name="Schneider 2008"/> A more colorful illustration of the confusion of the time is a quote from the French veterinarian Roche-Lubin in 1848 (cited by Maxime Schwartz): "In our land, the causes of scrapie are excessive copulation by rams; the rough fighting in which they engage among themselves; the sustained use of feeds that arouse them; leaping; violent exertion; rapid running when chased by dogs; loud thunder; bright sunshine in the first few days after shearing; and the frequent recurrence of heat among infertile [females]."<ref name="Schwartz Book">Template:Cite book</ref>

Discovery of spongiform change in scrapie

Another key event in the history of transmissible spongiform encephalopathies was the discovery of spongiform change (vacuolation) in the nervous system of sheep by Charles Besnoit and colleagues in the late 1890s.<ref name="Brown Bradley"/><ref name="Schneider 2008"/> Prior investigations had failed to identify pathologic features that were linked to the disease.<ref name="Schwartz Book"/> The realization that vacuolation is a characteristic of scrapie was a critical step toward the pathological definition of the transmissible spongiform encephalopathies in general.<ref name="Hadlow 1995">Template:Cite journal</ref>

Discovery of human spongiform encephalopathy

Hans Gerhard Creutzfeldt presented a case report of an unusual neurodegenerative disease in 1920, and this was followed by a description of five cases in 1921 that Alfons Maria Jakob felt were similar to Creutzfeldt's.<ref name="Katscher 1998">Template:Cite journal</ref> Walther Spielmeyer in 1922 then christened the disease "Creutzfeldt-Jakob disease".<ref name="Spielmeyer 1922">Template:Cite journal</ref> Subsequently, researchers have determined that Creutzfeldt's original case probably was not a spongiform encephalopathy, but that two of Jakob's first five cases could be confirmed as the disease that today is called Creutzfeldt-Jakob disease.<ref name="Katscher 1998"/> Although Jakob can be considered to have priority of discovery, "Creutzfeldt-Jakob disease" (CJD) remains the most frequently used name for the disease, especially in the English language literature.<ref name="Katscher 1998"/>

Proof that scrapie is transmissible

Prior to the 1930s, several scientists attempted to transmit scrapie by the introduction of diseased tissues into healthy sheep, but the experiments failed, possibly because the researchers did not account for the very long incubation period of scrapie.<ref name="Brown Bradley"/><ref name="Schneider 2008"/> Transmissibility was only established with certainty in the 1930s by experiments in which Jean Cuillé and Paul-Louis Chelle placed tissues from sick animals into healthy sheep.<ref name="Brown Bradley"/><ref name="Schneider 2008"/> Recognizing the unusually long incubation period for normally acquired scrapie, Cuillé and Chelle succeeded where others had failed by waiting more than a year for disease to appear.<ref name="Brown Bradley"/> Their experiments were the first to strongly implicate some type of infectious agent in the transmission of scrapie.<ref name="Schwartz Book"/> In 1961, Richard Chandler reported the transmission of scrapie to mice; the availability of a smaller, shorter-lived animal model (compared to sheep and goats) significantly accelerated subsequent investigations of disease mechanisms.<ref name="Poser 2002 Part 1">Template:Cite journal</ref><ref name="Brown Bradley"/>

Proof that human spongiform encephalopathies are transmissible

Based on Hadlow's recognition of the similarities between kuru and scrapie,<ref name="Poser 2002 Part 1"/> Daniel Carleton Gajdusek went on to demonstrate the transmissibility of kuru, CJD, and Gerstmann–Sträussler–Scheinker syndrome to nonhuman primates.<ref name="Gajdusek 1966"/><ref name="Gajdusek 1968"/><ref name="Masters 1981"/> Because of its rarity, Creutzfeldt-Jakob disease was little known prior to the discovery that human spongiform encephalopathies are transmissible.<ref name="Schwartz Book"/><ref name="Poser 2002 Part 1"/> The work of Gajdusek, in collaboration with researchers such as William Hadlow, Igor Klatzo, Elizabeth Beck, Michael Alpers and Clarence J. Gibbs, brought together two previously separate lines of research: one in veterinary medicine and the other in human medicine.<ref name="Schwartz Book"/> In 1976, Gajdusek shared the Nobel Prize in Physiology or Medicine with Baruch S. Blumberg "for their discoveries concerning new mechanisms for the origin and dissemination of infectious diseases".<ref name="Nobel 1976">Template:Cite web</ref> The transmissibility of spongiform encephalopathies to humans was further substantiated by the BSE crisis and the discovery of iatrogenic forms of prion disease (see Epidemiology, above).

Evidence that the infectious agent is unusual

In the 1960s, researchers began to confirm longstanding suspicions that the TSEs were caused by an extraordinary infectious agent: Iain Pattison demonstrated the resistance of the scrapie agent to heat and formaldehyde (which destroy most microbes and viruses) and, using ultraviolet and electron irradiation, Tikvah Alper concluded that the agent was extremely small, and that it was unlikely that it replicated via nucleic acids.<ref name="Schwartz Book"/><ref name="Poser 2002 Part 1"/> Around this time, John Stanley Griffith published a short commentary in which he proposed three ways in which an infectious agent might replicate without nucleic acids.<ref name=Griffith67>Template:Cite journal</ref> Griffith's 'second way' proposed that a normally produced cellular protein might adopt an abnormal shape that replicates by converting like proteins into the same shape, a hypothesis that anticipated the formalization of the prion concept in the 1980s.

The prion principle is established

In 1982, Stanley Prusiner coined the word 'prion' to refer to infectious agents that consisted primarily or exclusively of proteins.<ref name="Prusiner82">Template:Cite journal</ref> Research in the following years demonstrated that PrP is normally produced in the body and that mutations of PRNP are associated with prion diseases.<ref name="Nafe 2023"/> The public health importance of prions as infectious agents was underscored by the BSE crisis and iatrogenic prion disease in humans.<ref name="Brown Bradley"/> In 1997, Stanley Prusiner was awarded the Nobel Prize in Physiology or Medicine 'for his discovery of Prions - a new biological principle of infection'.<ref name="nobel">Template:Cite web</ref> In the 21st century, the legacy of the transmissible spongiform encephalopathies has expanded with the discovery that several (non-infectious) diseases involving the accumulation of abnormal proteins may be caused by a similar molecular mechanism. These include degenerative disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Lewy body dementia, tauopathies, systemic amyloidoses and others.<ref name="Walker 2006">Template:Cite journal</ref><ref name="Jucker 2013">Template:Cite journal</ref><ref name="Goedert 2015">Template:Cite journal</ref><ref name="Prusiner 2017">Template:Cite book</ref>

See also

• Proteinopathy
• Variably protease-sensitive prionopathy

References

• This entry incorporates public domain text originally from the National Institute of Neurological Disorders and Stroke, National Institutes of Health [1] Template:Webarchive and the U.S. National Library of Medicine [2]

External links

• Template:Cite journal